| 1 |
34568318 | MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia. | 2021 |
1 |
| 2 |
33068284 | Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. | 2020 Dec |
5 |
| 3 |
33218150 | Sunitinib-Containing Carborane Pharmacophore with the Ability to Inhibit Tyrosine Kinases Receptors FLT3, KIT and PDGFR-β, Exhibits Powerful In Vivo Anti-Glioblastoma Activity. | 2020 Nov 18 |
1 |
| 4 |
28990511 | Sunitinib in the Treatment of Thyroid Cancer. | 2019 |
4 |
| 5 |
29581831 | Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma. | 2018 Mar 6 |
1 |
| 6 |
29935772 | Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML. | 2018 Aug 1 |
2 |
| 7 |
30514344 | FLT3 inhibitors in acute myeloid leukemia. | 2018 Dec 4 |
1 |
| 8 |
29262547 | Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6. | 2017 Nov 28 |
1 |
| 9 |
27181063 | Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. | 2016 Jul |
1 |
| 10 |
27450971 | FLT3 Inhibitors for Treating Acute Myeloid Leukemia. | 2016 Oct |
1 |
| 11 |
27453754 | Metastatic clear cell renal carcinoma - an unusual response to Temsirolimus in second line therapy. | 2016 Apr-Jun |
1 |
| 12 |
25818407 | A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. | 2015 Jun |
1 |
| 13 |
26244574 | Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. | 2015 |
3 |
| 14 |
24424564 | Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study. | 2014 Dec |
1 |
| 15 |
24425345 | A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. | 2014 Apr |
1 |
| 16 |
24883179 | The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. | 2014 Jun |
2 |
| 17 |
25085632 | Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. | 2014 Aug 1 |
2 |
| 18 |
25089810 | Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia. | 2014 Oct 6 |
3 |
| 19 |
25691928 | Differences in growth promotion, drug response and intracellular protein trafficking of FLT3 mutants. | 2014 Nov |
2 |
| 20 |
23392356 | The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. | 2013 Jun |
1 |
| 21 |
23969938 | Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. | 2013 Oct 15 |
5 |
| 22 |
22080184 | A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. | 2012 Jun |
2 |
| 23 |
22391574 | Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells. | 2012 Aug |
1 |
| 24 |
23102636 | Strategic combination therapy overcomes tyrosine kinase coactivation in adrenocortical carcinoma. | 2012 Dec |
1 |
| 25 |
21469976 | Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma. | 2011 May |
2 |
| 26 |
21705501 | Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. | 2011 Aug 25 |
1 |
| 27 |
21771900 | Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation. | 2011 Oct |
1 |
| 28 |
22027642 | Sunitinib induced pyoderma gangrenosum-like ulcerations. | 2011 Nov 10 |
1 |
| 29 |
19940466 | Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review. | 2010 |
1 |
| 30 |
20520641 | Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib. | 2010 Aug |
2 |
| 31 |
20629553 | Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer. | 2010 Sep |
3 |
| 32 |
20733555 | FLT3 inhibitors for the treatment of acute myeloid leukemia. | 2010 Jun |
1 |
| 33 |
18534874 | Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. | 2009 Jul-Aug |
1 |
| 34 |
19017755 | Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. | 2009 Feb |
1 |
| 35 |
19453268 | Sunitinib in solid tumors. | 2009 Jun |
1 |
| 36 |
19467916 | FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. | 2009 Jun |
1 |
| 37 |
19844230 | Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. | 2009 Nov 17 |
1 |
| 38 |
17505827 | A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. | 2008 Mar |
1 |
| 39 |
17983653 | Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene. | 2008 Jun |
2 |
| 40 |
18082353 | Sunitinib in the management of gastrointestinal stromal tumours (GISTs). | 2008 Aug |
2 |
| 41 |
18192256 | Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. | 2008 Jan 15 |
2 |
| 42 |
18288997 | From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. | 2008 |
1 |
| 43 |
18483300 | Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. | 2008 May |
1 |
| 44 |
18537751 | Developments in targeted therapy of advanced gastrointestinal stromal tumors. | 2008 Jun |
2 |
| 45 |
18612155 | Activity of sunitinib in patients with advanced neuroendocrine tumors. | 2008 Jul 10 |
1 |
| 46 |
17296815 | Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. | 2007 Feb |
1 |
| 47 |
17327610 | Sunitinib: from rational design to clinical efficacy. | 2007 Mar 1 |
1 |
| 48 |
17367763 | Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. | 2007 May 4 |
1 |
| 49 |
17588358 | Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor. | 2007 Jul |
1 |
| 50 |
17591828 | Sunitinib: bridging present and future cancer treatment. | 2007 Jun |
1 |